INNOVATE Corp. Announces Major Regulatory Milestone: MediBeacon’s TGFR Monitor and Sensor Receive EU CE Mark

Key Highlights

• MediBeacon Inc., an equity method investment of INNOVATE Corp. (NYSE: VATE), has received the prestigious EU CE Mark under the Medical Device Regulation (MDR) for its TGFR™ Monitor and Reusable Sensor.
• This certification is a critical validation of the safety, quality, and performance of these devices, enabling their use in clinical trials across European sites.
• The TGFR™ System, which includes these newly certified devices, is designed for transdermal assessment of Glomerular Filtration Rate (tGFR), a key measure of kidney function.
• Lumitrace® (relmapirazin) injection, a core component of the TGFR system, is already approved in the U.S. and China, with European submission pending.
• The CE Mark is expected to enable wider international adoption and could be a potential catalyst for future revenue growth and valuation uplift for INNOVATE Corp.

Detailed Report

INNOVATE Corp. (NYSE: VATE) announced a significant regulatory achievement for its portfolio company, MediBeacon Inc., a medical technology leader in fluorescent tracer agents and their transdermal detection. On March 31, 2026, MediBeacon received CE Mark certification under the stringent EU Medical Device Regulation (MDR) 2017/745 for its TGFR™ Monitor and TGFR™ Reusable Sensor.

According to Steven Hanley, CEO and Co-Founder of MediBeacon, “Obtaining the EU CE Mark is a significant milestone for MediBeacon. As the TGFR™ System enters clinics in the U.S. and China, the CE Mark allows for potential use of the transdermal technology in clinical trials that include European sites. The achievement also underscores our commitment to meeting the highest quality and safety standards.”

About the TGFR™ System

The TGFR™ System is comprised of:

• TGFR™ Monitor (now CE marked in the EU)
• TGFR™ Reusable Sensor (now CE marked in the EU)
• Lumitrace® (relmapirazin) injection (approved in the U.S. and China; EU submission pending)
• TGFR™ Disposable Ring (CE marked)

This integrated system enables non-invasive, real-time measurement of kidney function (tGFR) at the point of care. The system works by measuring the rate at which Lumitrace, a highly fluorescent tracer agent, is cleared from the body via a sensor placed on the skin. Proprietary algorithms convert the resulting data into a clinically actionable measure of kidney function.

A phase 2 clinical study has validated that tGFR measured using Lumitrace matches that of iohexol (the standard GFR tracer) across a range of kidney function, as published in Kidney International (October 2024).

Potential Market Impact and Growth Drivers

• The CE Mark opens up the EU clinical trial market and, eventually, commercial opportunities across Europe for MediBeacon’s transdermal GFR technology.
• The technology is positioned as a potentially revolutionary, point-of-care method for assessing kidney function, which could significantly impact clinical practices, especially for patients at risk of renal complications.
• Additional applications for MediBeacon’s technology in gastroenterology, ophthalmology, and surgery are in various stages of clinical development, further expanding the addressable market.
• MediBeacon’s robust IP portfolio includes over 55 granted U.S. patents and more than 250 granted patents worldwide, offering strong competitive protection.

What Investors and Shareholders Should Know

• This regulatory achievement is highly price sensitive as it validates the technology and can accelerate commercialization in the EU, a major market for medical devices.
• Further expansion into clinical trials at European sites may lead to broader clinical adoption, revenue generation, and increased company valuation.
• Pending approval of the Lumitrace® (relmapirazin) injection in the EU is a future milestone investors should monitor closely.
• The company cautions that forward-looking statements are subject to risks, including the management of operational growth, misuse of the technology by end-users, and the ability to protect intellectual property.

About INNOVATE Corp.

INNOVATE Corp. is a diversified portfolio company with assets in Infrastructure, Life Sciences, and Spectrum, employing approximately 3,700 people across its subsidiaries.

Conclusion

The grant of CE Mark certification for the TGFR™ Monitor and Reusable Sensor represents a pivotal milestone for INNOVATE Corp. and its shareholders. It not only validates the robustness of MediBeacon’s technology in a highly regulated market but also sets the stage for potential commercial expansion and value creation. Investors should closely monitor the progress of European regulatory submissions and clinical adoption as important catalysts for the company’s future performance.

Disclaimer: This article is intended for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties, as outlined in INNOVATE Corp.’s filings with the SEC.

View INNOVATE Corp. Historical chart here